Japan based Takeda Pharmaceutical has partnered with Structural Genomics Consortium (SGC), to fund collective drug research that supports the discovery of new medicines.
Takeda’s contribution raises the SGC’s funds to $50m, strengthening the pre-competitive approach to drug research.
The SGC identifies and maps the three-dimensional structure of human proteins, which are the targets for drug discovery.
SGC Canada chief executive Aled Edwards said: "This is a strong endorsement of a novel business model, which relies on collaboration to share the risks of early-stage research, and reduce costs of drug discovery so we can get effective new medicines to market faster, and into the hands of physicians and patients sooner."
The SGC’s research network helps Takeda promote its drug discovery efforts by accessing new research.
In addition, SGC is also funded by the Canadian Institutes for Health Research, CFI, Genome Canada, the Ontario’s MEDI, and the Wellcome Trust.